ZNF503 and central nervous system cancer: Subsequent analysis of the single-cell dataset GSE131928 demonstrated that ZNF503-AS2 expression was mainly concentrated in malignant glioma (Fig 4N and 4O) and that ZNF503-AS2 was positively correlated with the cancer stemness index of glioma (R = 0.33, P < 0.001), suggesting that ZNF503-AS2 may be involved in the malignant progression of glioma (Fig 4P).